News

This is the first approval for this patient population in nearly a decade.

The FDA approved entrectinib for pediatric and adult patients with certain subtypes of solid tumors, including non-small cell lung cancer.

Oncology nurses can make the world of a difference when it comes to patient care, and it is crucial that they work together with other members of the treatment team to ensure the best outcomes, according to Sally Werner, MSHA, BSN, RN, senior vice president, affiliate relations at Cancer Support Community.

Workplace violence for healthcare workers – including nurses – is on the rise. Here’s what nurses need to know about the hot-button topic.

Hair, skin, or nail reactions commonly occur in patients treated with immunotherapy and targeted therapy for cancer.

PARP inhibitors have shown success in breast and ovarian cancer, and now they may be moving into the pancreatic cancer paradigm, too.

Robert M. Wenham, MD discusses evolving strategies in the ovarian cancer space.

The Food and Drug Administration (FDA) approved pexidartinib for the treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT).

About 25% of healthcare-related infections come from catheters, but there are steps nurses can take to mitigate this problem.

Here are the top 5 Oncology Nursing News stories for July 2019.

The FDA approved pembrolizumab to treat certain patients with recurrent, locally advanced or metastatic squamous cell carcinoma of the esophagus.

The FDA has approved darolutamide (Nubeqa) for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

The annual SONO meeting will feature the latest research and pressing topics for oncology nurses.

One expert discusses the arrival of immunotherapy, as well as other exciting advances, for the treatment of patients with small cell lung cancer.

Circulating tumor DNA (ctDNA) monitoring is clinically valid in predicting whether patients with unresectable, metastatic BRAF-mutant melanoma will benefit from dabafenib (Tafinlar) alone or in combination with trametinib (Mekinist).

Several key abstracts presented at the 2019 ASCO Annual Meeting demonstrated practice-changing potential in the prostate cancer field, said Celestia S. Higano, MD, FACP.

Optimizing the methods for preclinical research with an emphasis on patient-derived models, may help speed up the translation of new treatment advances from the laboratory to the clinic, according to a presentation by Charles M. Rudin, MD, PhD, at the 2019 International Lung Cancer Congress.

Many adolescent and young adult cancer survivors struggle in the post-cancer period. Oncology nurses can help ensure that they don’t fall through the cracks.

The Food and Drug Administration granted a priority review for a new drug application for tazemetostat. The drug will be used to treat a rare kind of soft tissue sarcoma that mainly affects young adults.

After months of debate, the Food and Drug Administration announced that they will be taking action to protect women from breast implant-associated anaplastic large cell lymphoma.

Nurse coordinators and other healthcare professionals must work together to provide comprehensive lung cancer screening programs.

The Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) for the treatment of blood cancers.

A recent study found that in some parts of the United States, more patients with cancer are treated by nurse practitioners than medical oncologists.

Immunotherapy has drastically changed the treatment landscape for non-small cell lung cancer, but how can practitioners decide who should get frontline chemotherapy, too?

Selective inhibitors for patients with non–small cell lung cancer with rare oncogenic drivers are showing high response rates in clinical trials, explained one expert.

Molecular testing has led to monumental strides in the field of ovarian cancer, offering women with the disease more personalized treatment options.

Oncology nurses may experience a high level of bullying from their peers, but steps can be taken to improve the environment of the workplace.

Patients with high-risk mantle cell lymphoma are likely to have their disease relapse, making investigations into novel treatments, such as CAR T-cell therapy, important.

Nurses, patients, and caregivers can now have crucial information regarding medical devices sent directly to their smartphone.

Some patients with advanced ovarian cancer may be better candidates for primary debulking surgery, while others should start chemotherapy.